No Sweat – Hyperhidrosis Patients Seek Broader Approvals; Botox Access An Issue

16 Nov 2017

• By Kate Rawson

US FDA not looking to reduce attendance at third-party patient meetings, which deliver 'bang for the buck.' Excessive sweating is first externally led PFDD meeting for a more common condition.

Female athletes running towards finish line on track field

Drug sponsors interested in hyperhidrosis research and development should focus on treatments that are effective for all types of excessive sweating – not just underarm or foot/hand sweating, according to patients participating in a patient-focused drug development meeting hosted by the International Hyperhidrosis Society in Washington, DC on Nov. 13.

While there are treatments for hyperhidrosis approved by the US FDA – like Botox injections and DrySol prescription antiperspirant –...